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Background: Intravenous immunoglobulin (IVIg) is an effective treatment in chronic inflammatory demyelinating
polyneuropathy (CIDP). In most patients, the optimal IVIg dose and regime is unknown. Polyvalent immunoglobulin
(Ig) G form idiotypic/anti-idiotypic antibody pairs in serum and IVIg preparations. We determined IgG dimer levels
before and after IVIg treatment in CIDP patients with the aim to explore their utility to serve as a surrogate marker
for treatment response.
Methods: IgG was purified from serum of five controls without treatment, as well as from serum of 16 CIDP
patients, two patients with Miller Fisher syndrome (MFS), and one patient with myasthenia gravis before and after
treatment with IVIg. IgG dimer levels were determined by size exclusion chromatography. IgG dimer formation was
correlated with clinical response to IVIg treatment in CIDP. Re-monomerized IgG dimer fractions were analyzed for
immunoreactivity against peripheral nerve tissue.
Results: IgG dimer levels were significantly higher in post- compared to pre-IVIg infusion samples. Low post-treatment
IgG dimer levels in CIDP patients were associated with clinical worsening during IVIg treatment. Re-monomerized IgG
dimer fractions from CIDP patients showed immunoreactivity against peripheral nerve tissue, whereas similarly treated
samples from MFS patients showed immunoreactivity against GQ1b.
Conclusion: Assessment of IgG dimer levels could be a novel approach to monitor CIDP patients during IVIg
treatment, but further studies in larger cohorts are warranted to explore their utility to serve as a potential
therapeutic biomarker for IVIg treatment response in CIDP.
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Chronic inflammatory demyelinating polyneuropathy
(CIDP) belongs to the most common immune-mediated
chronic disorders of the peripheral nervous system.
Abundant experimental evidence suggests that CIDP is
caused by an aberrant immune response that involves
autoreactive T cells, macrophages, and autoantibodies
[1–4]. However, despite extensive research over the last* Correspondence: helmar.lehmann@uk-koeln.de
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article, unless otherwise stated.decades, the target antigens of the humoral and cell-
mediated immune response are yet poorly defined.
Intravenous immunoglobulin (IVIg) is considered the
first-line treatment for CIDP, and several controlled
studies demonstrated its short- and long-term efficacy
[5–7]. The therapeutic effect of IVIg in CIDP is not fully
understood, but it is believed that different modes of
action are involved. These mechanisms include blockage
or modulation of Fcγ-receptors, regulation of T cell and
B cell activation, and alteration of inflammatory cyto-
kines [8–10]. In addition, there is evidence from other
autoimmune diseases that IVIg contains anti-idiotypic
(anti-Id) antibodies that are able to neutralize pathologicalis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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plexes [11–15].
IVIg preparations contain pooled IgG from different
donors and are mostly monomeric IgG. However, a
small percentage of polyvalent IgG form Id-anti-Id anti-
body dimers [16, 17]. Increased levels of IgG dimers
have been linked to adverse events during IVIg infusion
[18]. In contrast, there are experimental studies that sug-
gest beneficial effects of increased IgG dimer levels in
IVIg preparations [19].
Dimeric IgG is also detectable in the serum of healthy
individuals, although its amount compared to mono-
meric IgG is usually much lower than that in IVIg prep-
arations [20, 21]. Notably, it is currently unknown if
IVIg treatment influences the circulating IgG dimer con-
tent in humans with immune-mediated neurological
diseases.
We hypothesized that in CIDP, IVIg treatment may re-
sult in the formation of new Id-anti-Id complexes that
could be assessed by quantification of Ig dimers in post-
treatment serum of CIDP patients. We anticipated that
correlations between IgG dimer formation and clinical
response in individual patients could serve as a potential
surrogate marker for treatment response in CIDP, in
which optimal dose and regimen of IVIg is still unknown.
Moreover, purified IgG dimers, containing Id-anti-Id com-
plexes, could be employed as a novel approach to identify
idiotypic (auto)antibodies and their targeted antigens in
CIDP.
Methods
Patients
Sixteen patients with CIDP (mean age 64.4 ± 12.2, nine
males, seven females) were included in the study. All pa-
tients were diagnosed according to diagnostic criteria
developed by the Peripheral Nerve Society [22]. Fourteen
of 16 patients were on maintenance therapy with IVIg
and received a standard dose of 1 g/kg bodyweight
(BW). Blood was obtained immediately before and
30 min after IVIg infusion. All patients underwent a de-
tailed clinical workup prior to the IVIg infusion, which
also included assessment of the Medical Research Council
(MRC) sum score and Inflammatory Neuropathy Cause
and Treatment (INCAT) disability score as previously de-
scribed [23] (Table 1). Patients were considered stable
when INCAT score and MRC sum score remained un-
changed over 6 months of IVIg treatment, and worsening
to IVIg treatment was defined as change of either INCAT
or MRC sum score within 6 months.
In addition, blood was obtained from three patients
suffering from other immune-mediated neurological dis-
eases (myasthenia gravis, MG, n = 1; Miller Fisher syn-
drome, MFS, n = 2) immediately before and 30 min after
IVIg infusion and from five control patients (mean age51.8 ± 13.9, two females, three males). These included
patients with neurological diseases other than CIDP,
MG, or MFS (idiopathic cephalgia, peripheral facial nerve
paralysis (n = 2), subarachnoid hemorrhage, epilepsy).
The study is registered with ClinicalTrials.gov, number
NCT01655394, and approved by the local ethics commit-
tee (Ethics Committee University of Cologne, #12-182).
All patients gave written informed consent prior to inclu-
sion into the study.
Chromatographic separation of monomeric and dimeric
IgG fractions
Blood samples of patients were centrifuged (2000g,
15 min), and serum was prior to preparation of IgG
fractions diluted 1:4 with low-salt buffer (LS buffer)
containing 100 mM HEPES and 10 mM NaCl at pH 7.5.
All IgG purification experiments were performed on an
automated fast protein liquid chromatography system
(AKTA, GE Healthcare Bio-Sciences Corp.) using Unicorn
software (GE Healthcare Bio-Sciences Corp.) for analysis.
First, IgG fractions were purified from CIDP serum
samples using ion exchange chromatography columns
(HighTrap Q HP and HighTrap SP HP, GE Healthcare).
Columns were calibrated using LS buffer, and serum
samples were injected with a 1 ml sample loop. IgG frac-
tions were dissolved from the HighTrap SP HP column
using high-salt (HS) final buffer (100 mM HEPES and
500 mM NaCl at pH 7.5). A gradient was generated over
20 min at a defined flow rate. Collected IgG fractions
were re-concentrated to a 1 ml volume using a commer-
cial protein concentration kit (Pierce) according to the
manufacturer’s protocol.
The molecular weight (MW) profile of dimeric and
monomeric IgG was determined by gel filtration chro-
matography using an analytical-grade column (Superdex
200, GE Healthcare) and standard gel filtration buffer at
a flow rate of 0.5 ml/min.
SDS-PAGE analysis of monomeric and dimeric IgG fractions
The purity of dimeric and monomeric IgG fractions was
checked by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) using nUVview precast
Tris-HEPES gels containing 10 % polyacrylamide. Bands
were visualized under ultraviolet (UV) light after a 2-min
exposure time. As a standard, the low molecular weight
(LMW) references from Bio-Rad were used.
Detection of antibodies against GQ1b and AchR
Commercial ELISA plates (Sigma-Aldrich) were coated
with human GQ1b (Sigma-Aldrich). GQ1b-coated mi-
crotiter plates were blocked with 1 % BSA solution for
2 h at 4 °C and removed by washing with phosphate-
buffered saline (PBS) afterwards. Dimer IgG fraction
post-IVIg treatment was re-monomerized by dialyzing
Table 1 Clinical characteristics from CIDP patients with INCAT disability score, MRC sum score, and treatment history
Patient Sex Age Treatment before
sampling
IVIg treatment duration
before d1 (months)
INCAT
score d1
INCAT score
6 months
MRC
SS d1
MRC SS
6 months
Dimer content
pre-IVIg d1 (%)
Dimer content
post-IVIg d1 (%)
1 M 58 CS 0 2 2 58 58 1.3 3.0
2 M 62 CS, IVIg 9 2 2 58 58 3.8 11.3
3 M 67 CS, IVIg 16 1 2 60 60 5.4 5.5
4 M 34 CS, IVIg 10 1 2 52 52 2.4 2.4
5 F 79 CS, IVIg 28 7 6 52 52 4.6 9.3
6 M 61 IVIg 16 2 2 58 58 1.8 4.2
7 M 74 CS, IVIg 27 7 7 46 46 3.7 11.3
8 F 69 IVIg 5 0 0 60 60 2.7 6.0
9 F 73 CS, CP 6 4 7 52 47 2.3 4.1
10 M 48 CS, IVIg 6 3 1 58 58 2.1 3.4
11 F 56 IVIg 2 3 3 58 58 2.1 2.3
12 F 71 IVIg 8 0 0 60 60 3.9 7.4
13 F 79 IVIg 10 2 2 52 52 1,9 7,7
14 M 65 IVIg 10 2 2 58 58 0 4.2
15 F 78 CS, IVIg 12 1 1 58 58 3.7 6.2
16 M 57 - 0 2 2 60 60 0 3.9
CS cortisone, CP cyclophosphamide, SS sum score
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treatment monomeric IgG and post-IVIg treatment
monomeric and dimeric IgG fractions were added and
incubated overnight at 4 °C.
After washing with TWEEN-20 washing buffer,
peroxidase-conjugated anti-human IgG was added and
incubated for 2 h at 4 °C. After another washing step,
OPD solution (Sigma-Aldrich) was added according to
the manufacturer’s instructions for 30 min at room
temperature (RT). Finally, the stop solution was added
and optical density (OD) was measured within 30 min at
492 nm. Measurements were performed in triplets.
Acetylcholine receptor antibodies in pre- and post-
treatment samples were determined by standard radio
immune precipitation assay.
Immunohistochemistry using monomeric IgG
Dimeric IgG fractions were dialyzed against 10 mM
acetic acid, pH 4.0, at 4 °C for 24 h and stored at −20 °C
until further use.
Ten-micrometer sections from frozen rat sciatic nerve sam-
ples were cut on a cryostat and collected on Superfrost® Plus
glass slides (Thermo Scientific). Following incubation at −80 °
C overnight, sectionswere thawed at RTfor 1 h in a dry cham-
ber. After 1-h incubation in blocking solution (PBS containing
10 % normal goat serum and 0.4 % Triton X-100), sections
were incubated overnight in a humidified chamber at RTwith
antibodies and developed with appropriate secondary anti-
bodies. The following antibodies were used: monoclonal
mouse anti-myelin basic protein (Abcam, 1:500) andmonoclonal mouse anti-beta-III tubulin (Abcam, 1:500). For
immunofluorescence, we used fluorescein antibody (horse
anti-mouse IgG, 1:200; goat anti-human IgG). Sections were
co-stained with Hoechst 33342 (Thermo Scientific) and
mountedwith Fluoromount-G™ (SouthernBiotech).
Statistical analysis
Differences between serum samples and cell samples before
and after treatment were analyzed by t test (two groups), and
data were checked for normality using the Kolmogorov-
Smirnov test. A p value <0.05 was considered statistically sig-
nificant. Data is presented asmean +/- standard deviation.
Results
Analysis of IgG dimer content before and after treatment
with IVIg
We first analyzed the dimer content in serum IgG frac-
tions before (pre) and after (post) IVIg infusion in pa-
tients with CIDP, MG, and MFS. Dimeric IgG fractions
could be detected in most serum samples and varied
between 0 and 11.3 % of total IgG (Fig. 1a, b). In CIDP
patients, there was no association between IgG dimer
levels pre- and post-IVIg treatment and age, body
weight, or disease severity. IgG dimer levels were signifi-
cantly higher in post- compared to pre-infusion samples
(dimer content pre-IVIg 2.6 % ± 1.5, post-IVIg 5.8 % ± 2.9,
Fig. 1c). We also measured the percentage of IgG dimers
in five controls and found similar IgG dimer levels com-
pared to CIDP patients (dimer content 2.4 ± 1.3 %). Fur-
ther, we assessed the dimer content in different lots of two
Fig. 1 a Chromatography elution profile of representative pre-IVIg (black) and post-IVIg (grey) treatment sera. Dimeric IgG fractions (arrow) can be
detected in post-IVIg treatment samples. b Gel electrophoresis of purified IgG fractions. Heavy chain (56 kDa) and light chain (25 kDa) of CIDP
patient monomeric IgG fraction pre-IVIg (1) and post-IVIg (2) treatment could be detected. IgG purity in CIDP patient dimeric IgG fraction post-IVIg is
also shown (3) compared to IgG of healthy control (4) and commercial IVIg preparation (5). c Dimer content of CIDP patients (n = 16) pre- and
post-IVIg treatment. Dimer content is significantly increased after IVIg treatment. Change of dimeric IgG fraction in CIDP patients (n = 16)
pre- and post-IVIg treatment. d CIDP patients with stable/improving course of disease show significantly higher dimeric IgG compared to
worsening patients. e, f CIDP patients with stable/improving clinical course of disease after receiving either IVIg preparation #1 (e) or #2 (f) show
a significant increase of dimeric IgG fraction post-treatment (*p < 0.05; **p < 0.01; ***p < 0.001); ****p < 0.0001)
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and Gamunex®, Grifols) that were used in our patients and
found higher values (4.0 % ± 2.3 and 4.9 % ± 1.5, respect-
ively) compared to the average percentage in healthy
controls and pre-treatment serum samples from CIDP
patients.
High IgG dimer levels after IVIg treatment are associated
with disease stabilization
To assess the utility of IgG dimer levels as a surro-
gate marker for treatment response to IVIg, wegrouped our cohort of CIDP patients according to
their clinical response to IVIg treatment (stable/im-
proving vs. worsening) and calculated the change of
IgG dimer values in those two groups. CIDP patients
who showed improvement or stabilization of the dis-
ease course during IVIg treatment (n = 13) had sig-
nificantly elevated post-IgG dimer levels compared to
those who worsened under IVIg treatment (n = 3,
Fig. 1d). This difference could be detected irrespect-
ive which of the two available IVIg preparations were
used (Fig. 1e, f ).
Fig. 2 Anti-GQ1b antibody ELISA of samples from MFS patients.
Anti-GQ1b-antibodies are detectable in monomeric IgG fractions
pre- and post-IVIg treatment and in dimeric IgG fraction
post-IVIg treatment
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IVIg treatment
There is strong experimental evidence that IgG di-
mers, which are detectable in pooled human IgG
fractions from different individuals, consist of Id-anti-
Id antibody pairs. Therefore, it is likely that in CIDP,
post-treatment IgG dimers may also contain Id-auto-
antibodies and their anti-idiotypes. This hypothesis
cannot be directly validated in CIDP, since the target
antigens of the presumed autoantibodies in CIDP are
unknown.
To further characterize the nature of IgG dimers that
emerge after IVIg infusion, we collected monomeric and
dimeric IgG peaks from two patients with MFS and from
one patient with MG who were treated with IVIg. Pa-
tients #1 and #2 were seropositive for anti-GQ1b IgG
antibodies, and patient #3 had serum IgG antibodies
against acetylcholine receptors (71 nmol/l). We antici-
pated that IVIg dimers, which occur after IVIg treatment
as a result of Id-anti-Id binding, should contain measur-
able amounts of those autoantibodies. Therefore, we re-
monomerized the dimer fraction by dialyzing against
10 mM acetic acid at pH 4.0 and tested pre-IVIg treat-
ment monomeric IgG and post-IVIg treatment mono-
meric and dimeric IgG fractions for immune reactivity
against GQ1b and AchR, respectively. Monomeric
and dimeric IgG fractions of the patient with myas-
thenia displayed reactivity against AchR (pre-mono-
meric 969 ± 10.1 cpm, post-dimeric 127 ± 6.5 cpm,
post-monomeric 547.2 ± 16 cpm). Reactivity against
GQ1b could be shown in monomeric IgG fractions
pre- and post-IVIg treatment as well as to a higher
extent in dimeric IgG fraction post-IVIg treatment
(Fig. 2), suggesting that IgG dimers which occur after
IVIg treatment in those two patients are formed by
complexes that include autoantibodies and their pre-
sumed anti-idiotypes in IVIg preparations.
Post-IVIg dimeric IgG fractions show immune reactivity
against peripheral nerve fibers
Based on our experiments using GQ1b and AchR
antibody-positive sera, we further anticipated that IgG
dimers that occur after IVIg treatment in CIDP patients
may also contain autoantibodies and their IVIg-derived
anti-idiotypes. We therefore used post-IVIg treatment-
derived IgG dimers for screening for autoimmune re-
activity against neuronal or Schwann cell epitopes in
peripheral nerve fibers. Four out of ten tested dimeric
IgG samples stained axons and/or myelin of peripheral
nerve fibers (Fig. 3).
This immunofluorescence was not detected in mono-
meric or dimeric IVIg fractions, pre-dimeric IgG, or
from post-dimeric IgG derived from patients with MFS
or MG. Pre-treatment of tissue samples with methanol/chloroform abrogated staining with dimeric IgG, indicat-
ing that those epitopes are membrane associated. From
these data, we conclude that dimeric IgG contains anti-
bodies that may recognize epitopes expressed on periph-
eral axons and Schwann cells.
Discussion
Our study is the first that characterizes the nature of di-
meric IgG fractions that emerge during treatment with
IVIg in an immune-mediated neurological condition.
We demonstrate here that IVIg treatment induces the
formation of variable amounts of IgG dimers in CIDP
patients. The amount of newly formed IgG dimers in vivo
is associated with clinical stabilization and/or improve-
ment during IVIg treatment.
Consistent with previous studies that reported only
low levels of naturally occurring IgG dimers in healthy
individuals [21, 24, 25], we found that the overall
amount of IgG dimers in serum from controls and CIDP
patients was considerably small. In contrast, commercial
IVIg preparations contained higher amounts of IgG di-
mers. It is well known that pooled IgG from different
donors contains usually higher amounts of IgG dimers;
the amount of IgG dimers in commercial IVIg prepara-
tions varies between 5 and 15 %, depending on age,
storage, formulation, and presence of chemical stabi-
lizers [18, 19, 26].
The intravenous application of polyclonal IgG (IVIg)
resulted in a marked and rapid increase of IgG dimer
serum levels after treatment in most of our patients.
Those levels differed and were mostly higher as one
Fig. 3 Monomerized dimeric IgG fractions of CIDP patients stained axonal and myelin structures of the peripheral nerve. a Double immunofluorescence
labeling with Hoechst counterstain (cell nuclei, blue) revealed binding of monomerized dimeric IgG fractions (red) from CIDP patients to myelin basic
protein (green). b Control IgG showed no specific binding. Also, double immunofluorescence labeling with Hoechst counterstain (cell nuclei, blue)
showed binding of monomerized dimeric IgG from CIDP patients (red) to axonal nerve structures (beta-III tubulin, green) (c), whereas no binding was
observed in control staining (d) (scale bar 50 μm)
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mers that are present in commercial IVIg preparations
to the pre-existing IgG dimer amount. Therefore, it must
be concluded that IVIg infusion results in the spontan-
eous formation of novel immune complexes in vivo.
The association of high IgG dimer levels with clinical
stabilization in CIDP can be explained by interaction
and subsequent neutralization of autoantibodies with
anti-idiotypes that are present in IVIg preparations. IVIg
contains anti-Id against a broad range of autoantibodies
including anti-phospholipid [14], anti-DNA [15], anti-
thyreoglobulin [27], and anti-neutrophil cytoplasmic
antigen antibodies [28]. Those anti-Id interact with
variable regions of other antibody molecules to form Id-
anti-Id complexes, which are detectable in dimeric IgG
fractions [16, 21]. A direct proof that IgG dimers derived
from CIDP patients contain Id-anti-Id complexes would
be desirable but cannot be provided due to the lack of
commonly occurring, disease-specific autoantibodies inCIDP [29, 30]. However, our studies with post-treatment
samples from two patients with MFS and one patient
with MG support this concept and provide evidence that
IVIg contains also anti-Id against anti-GQ1b and anti-
AchR antibodies, respectively. It further argues against
the possibility that the IgG dimers in post-IVIg treat-
ment samples contain exclusively IgG aggregates from
IVIg preparations.
Although some of the monomerized IgG showed im-
munoreactivity against epitopes expressed on Schwann
cells and peripheral neurons, the overall number of
available samples was yet too small to define phenotype-
specific staining patterns. This is supported from recent
serological studies that reported novel disease-specific
antibodies only in very small proportions (8.6 and 4.2 %)
of cohorts of 46 [31] and 119 [32] CIDP patients. How-
ever, our immunolabeling studies with re-monomerized
IgG fractions provide proof of concept that Id-anti-Id
complexes that occur after IVIg treatment could be used
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tients in order to identify disease- or subgroup-specific
autoantibodies. This approach is quite different from
previous, mostly unsuccessful antibody screens that used
whole serum fractions from CIDP patients [29, 30, 33].
The fact that a considerable proportion of patients’ IgG
showed reactivity against axonal tissue or Schwann cells
may indicate an increased sensitivity of the strategy to
use dimer IgG fractions for antibody testing. However,
further validation studies with a larger cohort of patients
are necessary to independently confirm the usefulness of
IgG dimer quantification as a putative biomarker for
IVIg treatment in CIDP.
Limitations of our study are a considerably small num-
ber of patients, particularly the proportion of CIDP pa-
tients who worsened during IVIg treatment. In addition,
the patients in our cohort were only followed over a
time period of 6 months which restricts conclusions
about the utility of IgG dimers to serve as a putative
biomarker for CIDP. Future studies are also necessary to
determine dimer formation in IVIg-treatable conditions
that are not associated with autoantibodies, such as pri-
mary immunodeficiency.
Nevertheless, the results of our study support the no-
tion that anti-Id antibodies contribute to the beneficial
effect of IVIg treatment in CIDP. Furthermore, the
quantification of IgG dimer levels could be a feasible
approach to identify IVIg-responsive CIDP patients. Fur-
ther assessment of pre- and post-treatment IgG dimer
levels in larger patient cohorts is warranted to explore
their utility so serve as a potential biomarker for treat-
ment response to IVIg in CIDP patients.
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